甘精胰岛素联合格列吡嗪与瑞格列奈治疗2型糖尿病的疗效观察

Efficacy Observation of Therapeutic Efficacy and Safety of Repaglinide Combined Therapy of Glargine in the Treatment of Type 2 Diabetic Mellitus

目的:观察比较甘精胰岛素联合格列吡嗪与瑞格列奈治疗2型糖尿病的疗效及安全性。方法:将我院诊断的初发2型糖尿病患者110例随机均分为对照组和观察组。对照组每晚21:00注射甘精胰岛素1次,0.1U·kg-1;三餐前30min口服格列吡嗪,每次2.5mg。观察组每晚21:00注射甘精胰岛素1次,0.1U·kg-1;三餐前15min口服瑞格列奈,每次0.5mg。4个月后比较血糖控制及不良反应。结果:观察组血糖控制优于对照组,空腹C肽明显高于对照组(P<0.05),低血糖发生率低于对照组(P<0.05)。2组均未见明显不良反应。结论:甘精胰岛素联合瑞格列奈对2型糖尿病患者降糖疗效好且不良反应少。

OBJECTIVE：To observe the influence of glargine combined with glipizide or repaglinide on blood sugar of type 2 diabetic patients and adverse drug reactions. METHODS： 110 patients with newly diagnosed type 2 diabetes were randomly divided into combined therapy of glipizide group （control group） and combined therapy of repaglinidea group （observation group）. Control group was injected with glargine 0.1 U·kg-1 one time at 21：00 o’clock every night and took glipizide 2.5 mg each time 30 min before meals. Observation group was injected with glargine 0.1 U·kg-1 one time at 21：00 o’clock every night and took repaglinide 0.5 mg each time 15 min before meals. After 4 months, there will be a comparison about the glucose control and adverse drug reactions. RESULTS： The glucose control of observation group was better than that of control group. The fasting C peptide of observation group was higher than that of control group（P0.05）;the incidence of hypoglycaemia was lower than that of control group （P0.05）. There were no serines ADR in both groups. CONCLUSION： Glargine combined with repaglinide is effective for the therapy of type 2 diabetes with less adverse drug reactions.